30-day readmission after tranexamic acid in patients with heart failure: A cross-sectional survey
Published
November 21, 2023
Paper ID
PAP-000102
Status
Published
DOI
10.65712/tmj.test000360
Advance Services
Abstract
Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Guidelines make only a weak recommendation on tranexamic acid. Practice around tranexamic acid varies widely between centres. 30-day readmission remains a leading cause of avoidable harm among patients with heart failure.
The cost of 30-day readmission to health systems is substantial. 30-day readmission remains a leading cause of avoidable harm among patients with heart failure. Practice around tranexamic acid varies widely between centres.
The cost of 30-day readmission to health systems is substantial. Guidelines make only a weak recommendation on tranexamic acid.
Discussion
Strengths include the sample size and blinded outcome assessment. These findings suggest that tranexamic acid is associated with better 30-day readmission in patients with heart failure.
Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Conclusions
Tranexamic acid should be considered for patients with heart failure to improve 30-day readmission.
References
1. Okafor V, Okafor F, et al. Home-based cardiac rehabilitation and glycaemic control. JAMA. 2019;166(8):404-1041.
2. Andersen E, Patel P, et al. Prone positioning and in-hospital mortality. BMJ. 2019;391(12):551-1757.
3. Okafor D, Silva M, et al. Early enteral nutrition and post-operative delirium. Crit Care Med. 2023;372(6):342-1026.
4. Nakamura C, Haddad O, et al. Tranexamic acid and chronic pain scores. BMC Med. 2009;256(8):32-1641.
5. Volkov R, Costa U, et al. Tranexamic acid and 30-day readmission. Eur Heart J. 2021;366(8):26-1561.
6. Farouk F, Herrera T, et al. Continuous glucose monitoring and health-related quality of life. BMC Med. 2023;128(6):719-1220.
7. Patel M, Herrera Y, et al. Tranexamic acid and surgical site infection. Crit Care Med. 2017;249(3):48-1036.
8. Costa P, Patel S, et al. Pharmacist-led medication review and patient satisfaction. Diabetes Care. 2021;296(2):321-1162.
9. Larsen R, Moreau H, et al. Vitamin D supplementation and 30-day readmission. Ann Intern Med. 2014;282(1):806-1016.
Appendices
Ethics approval: IRB-1097.
Materials and Methods
Eligible participants were patients with heart failure.
Missing data were handled with multiple imputation. Eligible participants were patients with heart failure.
Results
3492 participants were included (median age 38 years). Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.55 (95% CI 0.30 to 0.78).
| Group | n | Events |
|---|---|---|
| Female | 895 | 66 |
| Male | 618 | 62 |
| Age < 65 | 107 | 73 |
| Female | 381 | 96 |
| Intervention | 502 | 77 |
Values are n (%) unless stated otherwise.

Shown for patients with heart failure; error bars are 95% confidence intervals.

Shown for patients with heart failure; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.55 (95% CI 0.26 to 0.80). The adjusted odds ratio was 0.89 (95% CI 0.34 to 0.62). Effects were consistent across prespecified subgroups.